Inclusion Criteria :

- Participant must be 18 years or older with confirmed diagnosis of malignant pleural
mesothelioma

- In countries where pemetrexed an approved mesothelioma treatment, the participant's
disease has progressed or relapsed following treatment with at least one prior
chemotherapy regimen with pemetrexed and either cisplatin or carboplatin OR In
countries where pemetrexed is not approved for mesothelioma, the participant's
disease has progressed or relapsed following treatment with at least one prior
chemotherapy regimen OR Pemetrexed is not the preferred therapy for the participant
and the participant's disease has progressed or relapsed following treatment with at
least one prior chemotherapy regimen

- Participants must have received no more than 2 prior systemic therapy regimens

- Participant has a Karnofsky performance scale status of ≥70

- Participant must have adequate bone marrow, liver, and kidney function and adequate
coagulation (per prespecified laboratory values)

Extension Phase

Inclusion Criteria:

- Participants who are receiving treatment with vorinostat and have not experienced
progression of mesothelioma

- Participants who were randomized to the placebo arm and are: 1) have a Karnofsky
performance scale status of ≥70; and 2) have adequate bone marrow, liver, and kidney
function and adequate coagulation (per prespecified laboratory values)

- Participants assigned to vorinostat who have discontinued study therapy for reasons
other than progression of mesothelioma, if the investigator is of the opinion that
the potential benefit outweighs potential risks associated with using vorinostat

Exclusion Criteria :

- Participant has been treated with a Histone deacetylase [HDAC] inhibitor

- Participant has an active infection for which they received treatment with
intravenous antibiotic, antiviral, or antifungal medications within 2 weeks of the
start of study drug.

- Participants with a "currently active" second malignancy. A malignancy is not
considered "currently active" if participants have completed therapy for the second
malignancy and are disease free from prior malignancies for >5 years

- Participant has uncontrolled brain metastases

- Participant has a known human immunodeficiency virus (HIV) infection or HIV-related
malignancy

- Participant is pregnant or breast feeding

- Participant has a history of gastrointestinal surgery or other procedures that might
interfere with the absorption or swallowing of the study drug

- Participants taking part in the pre-dose spot and post-first dose 24-hour urine
collections must exclude medications containing acetominophen or paracetamol for one
week prior to the start of vorinostat therapy and during the entire period of urine
collection

- Participants taking part in the pre-dose spot and post-first dose 24-hour urine
collections may not be using hemodialysis or peritoneal dialysis